Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Clesrovimab in Pre-Term and Full-Term Infants
NCT03524118Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2018
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of clesrovimab-cfor in respiratory syncytial virus infection (RSV), sponsored by Merck & Co.. Started Sep 2018; status: completed.
02
Drugs
clesrovimab-cfor
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03524118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03524118.